Related Experiment Videos
Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking
C Bandeira-Melo1, P T Bozza, B L Diaz
1Department of Physiology and Pharmacodynamics, Oswaldo Cruz Institute, Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil.
Abstract:
Tissue eosinophilia prevention represents one of the primary targets to new anti-allergic therapies. As lipoxin A4 (LXA4) and aspirin-triggered 15-epi-LXA4 (ATL) are emerging as endogenous "stop signals" produced in distinct pathologies including some eosinophil-related pulmonary disorders, we evaluated the impact of in situ LXA4/ATL metabolically stable analogues on allergen-induced eosinophilic pleurisy in sensitized rats. LXA4/ATL analogues dramatically blocked allergic pleural eosinophil influx, while concurrently increasing circulating eosinophilia, inhibiting the earlier edema and neutrophilia associated with allergic reaction. The mechanisms underlying this LXA4/ATL-driven allergic eosinophilia blockade was independent of mast cell degranulation and involved LXA4/ATL inhibition of both IL-5 and eotaxin generation, as well as platelet activating factor action. These findings reveal LXA4/ATL as a novel class of endogenous anti-allergic mediators, capable of preventing local eosinophilia.
Insights
Lipoxin A4 (LXA4) and aspirin-triggered 15-epi-LXA4 (ATL) analogues prevent allergic eosinophil buildup in tissues. These compounds act as natural anti-allergic signals, offering a new therapeutic target for eosinophil-related disorders.
Area of Science:
- Immunology
- Pharmacology
- Allergy Research
Background:
- Tissue eosinophilia is a key target for anti-allergic therapies.
- Lipoxin A4 (LXA4) and aspirin-triggered 15-epi-LXA4 (ATL) are endogenous "stop signals" implicated in resolving inflammatory conditions.
- Eosinophil-related pulmonary disorders often involve complex inflammatory pathways.
Purpose of the Study:
- To investigate the therapeutic potential of metabolically stable LXA4/ATL analogues in a rat model of allergen-induced eosinophilic pleurisy.
- To elucidate the mechanisms by which LXA4/ATL analogues modulate allergic inflammation and eosinophil migration.
Main Methods:
- Sensitized rats were challenged with allergen to induce eosinophilic pleurisy.
- Administration of in situ LXA4/ATL metabolically stable analogues.
- Assessment of pleural eosinophil influx, circulating eosinophilia, edema, neutrophilia, and inflammatory mediator levels (IL-5, eotaxin, platelet-activating factor).
Main Results:
- LXA4/ATL analogues significantly blocked allergen-induced eosinophil influx into the pleural cavity.
- Analogues increased circulating eosinophilia while reducing local tissue eosinophilia.
- Inhibition of IL-5 and eotaxin generation, and platelet-activating factor action was observed, independent of mast cell degranulation.
Conclusions:
- LXA4/ATL analogues demonstrate potent anti-allergic properties by preventing local tissue eosinophilia.
- These findings identify LXA4/ATL as a novel class of endogenous anti-allergic mediators.
- LXA4/ATL analogues represent a promising therapeutic strategy for managing eosinophil-driven inflammatory diseases.